

**4<sup>TH</sup> AML ACADEMY**  
**Management of Adult AML: Where are we in 2022**  
**Thursday 22<sup>nd</sup> & Friday 23<sup>rd</sup> September 2022**  
**IET Austin Court, 80 Cambridge Street, Birmingham B1 2NP**

**Organisers: Professor Charles Craddock (*Birmingham*)  
Dr Mike Dennis (*Manchester*) and Professor Steve Knapper (*Cardiff*)**

**Thursday 22<sup>nd</sup> September**

**Chair: Professor Charles Craddock, *Birmingham***

16.00	Introduction	
16.05	Key results from the NCRI AML18 and AML19 trials	Professor Nigel Russell, <i>Nottingham</i>
16.35	Ensuring inclusion and diversity in AML trial recruitment	Mr Ian Thomas, <i>Cardiff</i>
16.45	VICTOR	Dr Richard Dillon, <i>London</i>
17.00	Transplant trials	Dr Wendy Ingram, <i>Cardiff</i>
17.20	<i>Coffee</i>	
17.45	Supportive care / IMPACT	Professor Simon Stanworth, <i>Oxford</i> or Dr Justin Loke, <i>Birmingham</i>
18.05	Planned studies in fit newly diagnosed AML	Professor Charles Craddock, <i>Birmingham</i> & Professor Steve Knapper, <i>Cardiff</i>
18.25	EVOLVE	Dr Mike Dennis, <i>Manchester</i>
18.45	Relapse trials	Dr Pramila Krishnamurthy, <i>London</i>
19.05	Understanding alloreactive T cell targeting of leukaemia for therapeutic application	Professor Paresh Vyas, <i>Oxford</i>
19.30	<i>Summary and Close of Day 1</i>	
19.40	Drinks Reception	
20.00	Dinner	

**Friday 23<sup>rd</sup> September**

08.30	<i>Coffee and breakfast rolls</i>	
	<b>Plenary Session</b> <b>Novel therapeutic strategies in patients unfit for intensive chemotherapy</b>	<b>Chair: Dr Mike Dennis, <i>Manchester</i></b>
08.50	Optimising outcomes using Venetoclax based regimens	Dr Daniel Pollyea, <i>Colorado, USA</i>
09.30	Case based discussions	Dr Daniel Pollyea, <i>Colorado, USA</i> Dr Vidhya Murthy, <i>Birmingham</i> Dr David Taussig, <i>London</i>
10.10	<i>Coffee and networking</i>	

## Plenary Session

- 10.35 Translating genomics into clinical practice:  
Lessons from UK AML Trials
- 11.05 Familial leukaemia
- 11.30 Pre leukaemia and leukaemia prevention
- 11.55 Which patients with AML should we transplant  
and how?
- 12.25 *Lunch*

**Chair: Professor Steve Knapper, Cardiff**

Professor Brian Huntley, *Cambridge*  
Professor Paresh Vyas, *Oxford*

Dr Ana Rio-Machin, *London*

Professor George Vassiliou, *London*

Dr Victoria Potter, *London*

## David Grimwade Memorial Lecture

- 13.10 What's new in the 2022 ELN AML classification?  
Discussion

**Chair: Professor Charles Craddock, Birmingham**

Professor Harmut Dohner, *Ulm, Germany*

## Best AML papers 2022

- 13.55 x 3 papers

**Chair: Dr Priyanka Mehta, Bristol**

Dr Anjum Khan, *Leeds*  
Dr Pramila Krishnamurthy, *London*  
Dr Emma Searle, *Manchester*

- 14.45 *Coffee*

## Debate

- 15.10 MRD measurement has no role in the routine  
management of adult patients with non NPM1  
mutated AML

**Chair: Professor Steve Knapper, Cardiff**

**Debaters:**  
Dr Lynn Quek, *London*  
Dr Sudhir Tauro, *Dundee*  
Dr Rachel Protheroe, *Bristol*  
Dr Jiri Pavlu, *London*

- 16.00 Close

**Professor Charles Craddock, Birmingham**

## Platinum Sponsors

abbvie

Celgene | Bristol Myers Squibb  
Company

## Gold Sponsors

astellas

Jazz Pharmaceuticals

medac  
PHARMA

SERVIER  
Oncology

*With thanks to the sponsors who have had no input into the programme content or choice of speakers*